Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
M2 Ingredients Inc. operates in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These matters are distributed across 2 distinct examiners, indicating that each pending application is being handled by a different individual. This distribution prevents a concentration of workload under any single examiner and allows for diverse perspectives on the company's filings.
The prosecution activity is spread across 2 distinct art units. This suggests that the company's filings cover diverse technical sub-sectors within the Biotechnology & Pharmaceuticals field, requiring adherence to different departmental standards. Jacob A Boeckelman is the busiest examiner for the portfolio, managing 1 pending office action. Because the number of pending actions matches the number of examiners, no single individual is currently overseeing a concentration of the company's workload. Navigating 2 distinct art units and 2 examiners requires the company to adapt to various specialized technical requirements simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §101 + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| TURNER, FELICIA C | 1 | 26.2% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 54d |
| 18514846 | Hericium erinaceus DESIGNATED AS STRAIN M2-102-10 AND COMPOSITIONS, PRODUCTS, AND METHODS THEREOF | TURNER, FELICIA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 54d |
| 18514846 | Hericium erinaceus DESIGNATED AS STRAIN M2-102-10 AND COMPOSITIONS, PRODUCTS, AND METHODS THEREOF | TURNER, FELICIA C | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18516756 | Cordyceps Militaris Designated as Strain M2-105-04, Compositions, Methods of Making, Methods of Using and Methods for Treating Mammals | BOECKELMAN, JACOB A | 1655 | §101 | Final Rejection | 54d | Pending | Nov 21, 2023 |
| 18514846 | Hericium erinaceus DESIGNATED AS STRAIN M2-102-10 AND COMPOSITIONS, PRODUCTS, AND METHODS THEREOF | TURNER, FELICIA C | 1793 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialM2 Ingredients Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jacob A Boeckelman has the most, with 1 of M2 Ingredients Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
